

AMERICAN COLLEGE of CARDIOLOGY | Ohio CHAPTER | The 26th Annual Meeting

FFR and CTA: When Evaluating Anatomy Isn't Enough

October 15, 2016

Subha V. Raman, MD, MSEE, FACC, FAHA
Professor and Joseph M. Ryan, MD Chair in Cardiovascular Medicine
Program Director, Cardiovascular Diagnostics Fellowship
Medical Director, CMR/CCT




Disclosures




- Research support from NIH, Siemens

64 year-old male with bradycardia pre-colonoscopy

- Atropine given, cardiology evaluation advised; 'asymptomatic'
- PMH: OSA on CPAP
- SoCH: karate instructor, nonsmoker
- FH: father died of suspected MI in his 70s
- Exam: 150/80, HR 78, 71 kg, 1.8 m
- Labs: LDL 121, HDL 60, TG 68, total 195




Typical evaluation of stable patients with suspected CAD:

 <p>History, Physical, Labs, ECG</p>	 <p>± Stress Electrocardiography</p>	 <p>Invasive coronary Angiography ± FFR</p>
<input type="checkbox"/> Pre-test Likelihood	<input type="checkbox"/> Post-test Likelihood <input type="checkbox"/> Presence/location of ischemia	<input type="checkbox"/> Stenosis + ischemia <input type="checkbox"/> Therapeutic revascularization

64 y/o active male with bradycardia, OSA, HTN


- What next?
 1. Reassurance
 2. Stress testing
 3. Coronary CTA
 4. Invasive angiography



Outline

- Room for improvement? Established utility of CTA
- FFR-CT – underlying principles
- FFR-CT – trial data
- FFR-CT – Practical aspects (time to process, quality of CTA data, cost/reimbursement) & case illustrations
- Ongoing trials, future directions/other apps (anomalies, stents, ACS prediction)


Suspected but no known CAD: nearly 2/3 without obstructive disease by ICA



analysis of ~400,000 patients at > 650 US hospitals

Patel M et al. NEJM 2010.

Diagnostic Performance of Coronary CTA



Accuracy Requires ≥64 Detector Rows, HR Control

- Meta-analysis of 89 CTA studies, N=7,516 patients
 - Five (5) multi-center trials; per-patient analysis

Table. Diagnostic Accuracy Data for CT, MRI, and Covariate Analyses

Imaging Method	Mean Sensitivity (95% CI), %	Mean Specificity (95% CI), %	Area Under the Curve (95% CI)	Positive Likelihood Ratio (95% CI)	Negative Likelihood Ratio (95% CI)
MRI (1)					(0.14-0.25)
CT (89)					(0.02-0.04)
Scanner rows					(0.02-0.04)
Scanner rows > 16†		98.1 (97.0-99.0)		89.4 (86.0-92.0)	(0.02-0.19)
Covariates					
Heart rate					
< 60 beats/min		99.0 (98.1-99.5)		85.8 (79.4-90.5)	
≥ 60 beats/min		96.2 (94.7-97.3)		87.7 (84.1-90.5)	
P value		<0.001		0.55	
Heart rate					
< 60 beats/min		96.2 (94.7-97.3)		87.7 (84.1-90.5)	
P value		<0.001		0.55	


Ann Int Med 2010.

Diagnosis of Obstructive CAD

Test	Sensitivity	Specificity
Exercise ECG treadmill ¹	68%	77%
Exercise Echo treadmill ²	86%	81%
Dobutamine Echo ²	~85%	~85%
Treadmill stress nuclear ³	87%	73%
Pharmacologic stress nuclear ³	89%	75%
Coronary CTA ⁴	94%	83%

- ACC/AHA 2002 Guideline Update for Exercise Testing
- ACC/AHA/ASE 2003 Guideline Update for the Application of Echocardiography
- ACC/AHA/ASE 2003 Guideline Update for the Application of Echocardiography
- ACC/AHA/ASE 2003 Guideline Update for the Application of Echocardiography

We Don't Want to Miss Significant Left Main Disease




Berman D et al. J Nuc Cardiol 2007.

Clinical Outcomes: PROMISE Trial

- 10,003 patients presenting for new CAD evaluation
- Randomized to CTA or stress testing (referring doc's choice)

	Favors CT	Neither	Favors Stress Testing	
Outcomes at 2 years		X		
Outcomes at 1 year	X			33% decrease death/ MI (p=0.04)
Radiation dose			X	12 vs. 10 mSv
Radiation dose vs. SPECT	X			12 vs. 14 mSv
Diagnostic Performance	X			Cath Normalcy 3.4 vs 4.3%
Triage to surgical revascularization	X			2-fold increase CABG
Primary Preventive Tx	X			2-fold increase statins
Quality of Life		X		Similar
Cost		X		<\$50 difference



National Institute for Health and Care Excellence

NICE National Institute for Health and Care Excellence

Search NICE...

Home > NICE Guidance > Conditions and diseases > Cardiovascular conditions > Stable angina



CTA outperformed ETT for each of the comparative measures described:

- excluded coronary artery disease more effectively (97.1% vs. 72.9%)
- led to fewer second-line investigations (8.8% vs. 23.5%)
- the total cost per patient to reach diagnosis was significantly lower (-20.3%)



Chest pain of recent onset (standing committee A update): Addendum consultation

You can now review and comment on this draft guideline.
The consultation closes on 31 May 2016 at 5pm

Department of Health





Reference "Gold" Standard for Ischemia: Fractional Flow Reserve



FFR ≤ 0.80 or ≤ 0.75 considered diagnostic of lesion-specific ischemia

Pijls NH et al. J Am Coll Cardiol. 2007; Pijls NH et al. J. Am. Coll. Cardiol. 2010


Lesion-specific ischemia exhibits an unreliable relationship with angiographic stenosis



21% of 30-50% angiographic stenoses had +FFR, 19% of 90-95% stenoses have -FFR

Layland et al EHU 2014


50-70% stenoses




70-90% stenoses

Tonino PA et al. JACC 2010.

FAME : FFR-Guided Therapy is Superior to Angiography-Guided Therapy



FAME 2: FFR-Guided Revascularization is Superior to OMT Alone



Tonino et al. NEJM 2009; DeBruyne et al. NEJM 2012.

FFR can now be derived from CTA

1. Uses standard (high quality) CTA images
2. No added radiation, contrast, medications
→ FFR at any point in the coronary tree

Functional Significance of CAD: FFR-CT

- Pressure loss determined by serial lesions
- Perfusion territory affects flow and pressure loss
- Allometric scaling: Q_{cor} proportional to $LVM^{0.75}$
- Maximum reduction in coronary resistance i.e. response to adenosine can be modeled

Choy & Kassab. J Appl Physiol 2008.
Wilson RF et al. Circ 1990.

Patient-specific Arterial Geometry by Coronary CTA

A

3D Mesh Generation

B

Subvoxel Resolution Evaluation

C

Coronary Artery Segmentation

It's a process...

D

3D Mesh Generation

E

Quantification of Rest Coronary Flow

F

Calculation of Microvascular Resistan

G

Computation of Hyperemic Changes

H

Computational Fluid Dynamics

Mass Conservation (1 equation):

$$\frac{\partial \rho}{\partial t} + \nabla \cdot (\rho \mathbf{u}) = 0$$

Momentum Balance (3 equations):

$$\rho \frac{d\mathbf{u}}{dt} = -\nabla p + \nabla \cdot \boldsymbol{\tau}$$

FFR_{CT}

1 – Patient Specific Arterial Geometry


- Finite Element Modeling for pulsatile blood flow
- Millions of vertices and elements, more at boundaries

LAO135 CRA52

C.A. Taylor, T.J.R. Hughes, and C.K. Zarins, (1996) Computers in Physics, Vol. 10, No. 3, pp. 224-232; C.A. Taylor, T.J.R. Hughes, and C.K. Zarins, (1998) Finite Element Modeling of Blood Flow in Arteries. Computer Methods in Applied Mechanics and Engineering, Vol. 158, Nos. 1-2, pp. 155-196.

2 – Form-Function Relationships

- **Allometric Scaling (Morphometry) Laws:** Relate mass (size) of object to shape, anatomy and physiology
 - Abundant physiologic information from anatomic data
 - Examples:
 - AV fistula enlargement d/t chronic incr. in blood flow
 - High-grade stenosis vessel smaller d/t chronic decrease in blood flow



Coronary Flow Related to Size

- **Murray's Law is a Homeostatic process**
 - Adaptive mechanism
 - Endothelium → remodel coronary size to maintain homeostatic level of shear stress
- **Poiseuille's Equation: Q / Diameter Relationship**
 - Describes steady flow of viscous fluid in circular cylinder
 - Blood vessels change in caliber based on flow and wall shear stress sensed by endothelial cells
 - Q = flow rate
 - D = diameter of vessel
 - T_w = wall shear stress
 - η = fluid viscosity


$$Q = \frac{\pi}{32\mu} \tau_w d^3$$

Flow = d^3 if wall shear stress maintained

Taylor et al. J Am Coll Cardiol 2010; Leipsic et al AJR 2013 Schuijff et al. J Am Coll Cardiol 2006, Schuijff et al. Heart 2008

Form-Function Relationships (cont.)


Resting coronary flow proportional to myocardial mass



$$Q_c^{rest} \propto M_{myo}^\beta$$

3 – Patient-Specific Physiology



- **Boundaries:** aortic inlet, aortic outlet, coronary outlets and lateral surface
- Lumped parameter model to enforce relationship b/w pressure and flow




- Pulsatile flow in relation to time-varying intramyocardial pressure
 Leipsic et al AJR in press : Leipsic et al JCCT 2012 Taylor CA and Min JK J Am Coll Cardiol 2013, C.A. Taylor, T.J.R. Hughes, and C.K. Zarins, (1996) Computers in Physics, Vol. 10, No. 3, pp. 224-232; C.A. Taylor, T.J.R. Hughes, and C.K. Zarins, (1998)

4 – Induction of Hyperemia

- Heart lacks O₂, breakdown of ATP results in release of adenosine → vasodilation
- Exogenous adenosine elicits hyperemia by forcing complete smooth muscle cell relaxation



- FFR_{CT} includes adenosine effect on resistance of microcirculation
- Underlies dose for pharmacologic stress testing and invasive FFR




Does It Work? 3 Prospective Multicenter Trials

	DISCOVER-FLOW	DeFACTO	NXT
Primary end point	Per pt. diag accuracy	Per pt. diag accuracy; lower limit 95% CI 0.7	Per pt. AUC
Study sites/ countries	4 / 3	17 / 5	10 / 8
CT training of site	Yes	No	Yes
FFR training of site	No	No	Yes
CT quality check	No	No	Yes
CT results reading	Core lab	Core lab	Site
FFR results report	Site	Site	Site with core lab overview
Vessel size for inclusion	≥ 2.0 mm	≥ 1.5 mm	≥ 2.0 mm
Use of NTG with CT	?	75%	99.6%





Koo et al. JACC 2011; Min JK et al. JAMA 2012; Norgaard BL et al. JACC 2014



Per-Patient Diagnostic Performance: NXT Trial



FFR-CT correctly reclassified 68% of CT false ⊕ to true negatives

Nergaard BL et al. JACC 2014.









Importance of adherence to best practice for CTA

- SL NTG
- HR control
- Contrast opacification of the coronaries
- Minimal right heart/SVC contrast
- Minimal respiratory artifact


Leipsic et al AJR 2014

Clinical Utility: PLATFORM Trial


- Prospective Longitudinal Trial of FFR_{CT}: Outcome and Resource IMpacts
 - Prospective, controlled, pragmatic comparative effectiveness trial utilizing a comparative cohort design
 - 584 patients with suspected CAD (pre-test likelihood of 20-80%) were enrolled at 11 centers in 6 EU countries
- Primary Endpoint:** Patients with a planned ICA
 - Are patients evaluated using a **CTA/FFR_{CT} guided strategy** less likely to undergo ICAs that show **no obstructive CAD**?



Which Dictates ACS – Adverse Plaque or Adverse Hemodynamic Characteristics?




Future of FFR-CT: Virtual Stenting




Courtesy J Min, MD


44 patients
Accuracy 96%
Sens / Spec 100% / 96%



Other Applications



Optimal Diagnostic Approach to Symptomatic CAD?



Back to our patient:
64 y/o active male with bradycardia, OSA, HTN

Summary

- CAD anatomy + physiology → better outcomes
 - FFR-CT represents a significant advance in evaluating CAD
 - Superior diagnostic accuracy of 86% for lesion-specific ischemia
- Typical referrals to coronary CTA may need to change to realize full incremental value
- Availability, cost, & processing time should improve

Thank you

- Team OSU CMR/CCT
- Johnathon Leipsic, MD - University of British Columbia
- James Min, MD - Dalio Institute/Weill-Cornell Medical Center

